Pargluva won’t launch within next two years, Bristol-Myers Squibb says

Share this article:
Bristol-Myers Squibb said its diabetes drug Pargluva (muraglitazar) won't be launched in 2006 or 2007, The Wall Street Journal reported today.
In the newspaper report, the company said it still has not decided whether it will pursue marketing approval for Pargluva and likely won't make a decision before next year.
Pargluva is the first drug in what had been considered a promising new class of drugs for millions of diabetics.
In October, researchers released data indicating that use of the drug more than doubles the risk of life-threatening cardiovascular complications.
The Cleveland Clinic researchers, who also pointed out the heart risks of Vioxx in 2001, said the agency should not approve the drug until additional research is conducted.
Also in October, the FDA issued an approvable letter, indicating the drug could be cleared for marketing once additional information to be provided by BMS is received and reviewed.
Bristol-Myers Squibb said it could take five years to obtain this additional data and that the company was considering a range of options, including additional studies or terminating further development. "We're still convinced that this is an important product," Lamberto Andreotti, president of the company's worldwide pharmaceuticals division, told The Journal adding that the company remains in discussions with the FDA over Pargluva.
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...